Literature DB >> 15526357

Epstein-Barr virus in hepatocellular carcinogenesis.

Wei Li1, Bao-An Wu, Yong-Ming Zeng, Guang-Can Chen, Xin-Xin Li, Jun-Tian Chen, Yu-Wen Guo, Man-Hong Li, Yi Zeng.   

Abstract

AIM: In recent years, studies have suggested that Epstein-Barr virus (EBV) is associated with HCC. The present study was to determine the prevalence of EBV in HCC patients, and whether EBV acted synergistically with hepatitis viruses in HCC carcinogenesis.
METHODS: Liver tissue 115 HCC patients and 26 non-carcinoma patients were studied. Polymerase chain reaction (PCR) was performed to detect EBV BamHI W DNA, EBV LMP1 DNA, HBV X DNA, and HBV S DNA. Reverse transcription PCR (RT-PCR) was performed to detect HCV RNA and HDV RNA. Immunohistochemistry was performed to detect LMP1, HBsAg, HBcAg and HCV. The positive ratios were compared between HCC group and control group by chi2 test.
RESULTS: Totally, 78 HCC samples whose beta-globulin DNA was positively detected by amplified PCR were selected. PCR was performed in all cases for EBV DNA and HBV DNA. RT-PCR was performed in 18 cases for HCV RNA and HDV RNA. EBV BamHI W and EBV LMP1 were positive in 18 and 6 cases, respectively. HBV X gene and HBV S gene were positive in 42 and 27 cases respectively. HCV was positive in one of the 18 cases, and none was positive for HDV. The positive rates were 28.2% (22 of 78) for EBV DNA (BamHI W and/or LMP1) and 56.4% (44 of 78) for HBV DNA (X gene and/or S gene) respectively. In addition, 12 cases were positive for both EBV DNA and HBV DNA. Among the 26 cases in the control group, 2 cases were positive for EBV BamHI W, 4 positive for HBV X gene and 3 positive for HBV S gene. The positive rates were 8.0% (2 of 26) and 23.1% (6 of 26), respectively, for EBV DNA and HBV DNA. The result of DNA sequencing of BamHI W was 100% homologous with the corresponding sequence of B95-8. There was significant difference in EBV infection rate between HCC patients and controls (chi2 = 4.622, P<0.05). The difference in HBV infection rate was also significant (chi2 = 8.681, P<0.05). However, there was no obvious correlation between HBV and EBV in HCC patients (chi2 = 0.835, P>0.05). LMP1, HBV (HBsAg, HBcAg) and HCV were detected positively in 25, 45 and 6 of 78 cases of HCC tissues respectively. In the 26 control cases, the corresponding positive cases were 2, 4 and 0. The difference in EBV infection rate between HCC patients and control cases was statistically significant (chi2 = 6.02, P<0.05). The difference in HBV infection rate was also statistically significant (chi2 = 10.03, P<0.05). In the 25 cases with positive LMP1 expression, 6 were in the nuclei of tumor cells, 9 in the cytoplasm of tumor cells and 10 in mesenchymal lymphocyte cytoplasm.
CONCLUSION: The existence of EBV infection in HCC tissues suggests that EBV may be involved in the hepatocellular carcinogenesis in China. HBV infection may be a major cause of HCC. There is no correlation between EBV and HBV in the development of HCC. The prevalence of HCV infection is low in our area, and HDV appears not to play a direct role in hepatocellular carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15526357      PMCID: PMC4576219          DOI: 10.3748/wjg.v10.i23.3409

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  24 in total

1.  No direct role for Epstein-Barr virus in American hepatocellular carcinoma.

Authors:  P G Chu; Y Y Chen; W Chen; L M Weiss
Journal:  Am J Pathol       Date:  2001-10       Impact factor: 4.307

Review 2.  Overview of Epstein-Barr virus-associated diseases in Japan.

Authors:  Hiroshi Wakiguchi
Journal:  Crit Rev Oncol Hematol       Date:  2002-12       Impact factor: 6.312

Review 3.  Persistence of the Epstein-Barr virus and the origins of associated lymphomas.

Authors:  David A Thorley-Lawson; Andrew Gross
Journal:  N Engl J Med       Date:  2004-03-25       Impact factor: 91.245

4.  Detection of Epstein-Barr virus in invasive breast cancers.

Authors:  M Bonnet; J M Guinebretiere; E Kremmer; V Grunewald; E Benhamou; G Contesso; I Joab
Journal:  J Natl Cancer Inst       Date:  1999-08-18       Impact factor: 13.506

5.  Enzymatic amplification of beta-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia.

Authors:  R K Saiki; S Scharf; F Faloona; K B Mullis; G T Horn; H A Erlich; N Arnheim
Journal:  Science       Date:  1985-12-20       Impact factor: 47.728

6.  No significant association of Epstein-Barr virus infection with invasive breast carcinoma.

Authors:  P G Chu; K L Chang; Y Y Chen; W G Chen; L M Weiss
Journal:  Am J Pathol       Date:  2001-08       Impact factor: 4.307

7.  Absence of Epstein-Barr virus DNA in the tumor cells of European hepatocellular carcinoma.

Authors:  Jia Junying; Kathrin Herrmann; Gillian Davies; David Lissauer; Andrew Bell; Judith Timms; Gary M Reynolds; Stefan G Hubscher; Lawrence S Young; Gerald Niedobitek; Paul G Murray
Journal:  Virology       Date:  2003-02-15       Impact factor: 3.616

Review 8.  Epstein-Barr virus-associated carcinomas: facts and fiction.

Authors:  Kathrin Herrmann; Gerald Niedobitek
Journal:  J Pathol       Date:  2003-02       Impact factor: 7.996

Review 9.  Epstein-Barr virus, the TCL-1 oncogene and Burkitt's lymphoma.

Authors:  Andrew Bell; Alan B Rickinson
Journal:  Trends Microbiol       Date:  2003-11       Impact factor: 17.079

10.  Lack of evidence for an association of Epstein-Barr virus infection with breast carcinoma--another point of view.

Authors:  María Victoria Preciado
Journal:  Breast Cancer Res       Date:  2003       Impact factor: 6.466

View more
  6 in total

1.  Chronic Epstein-Barr virus-related hepatitis in immunocompetent patients.

Authors:  Mihaela Petrova; Maria Muhtarova; Maria Nikolova; Svetoslav Magaev; Hristo Taskov; Diana Nikolovska; Zahariy Krastev
Journal:  World J Gastroenterol       Date:  2006-09-21       Impact factor: 5.742

Review 2.  Epstein-Barr virus: silent companion or causative agent of chronic liver disease?

Authors:  Mihaela Petrova; Victor Kamburov
Journal:  World J Gastroenterol       Date:  2010-09-07       Impact factor: 5.742

Review 3.  Unboxing the molecular modalities of mutagens in cancer.

Authors:  Smita Kumari; Sudhanshu Sharma; Dia Advani; Akanksha Khosla; Pravir Kumar; Rashmi K Ambasta
Journal:  Environ Sci Pollut Res Int       Date:  2021-10-05       Impact factor: 5.190

4.  EBV Chronic Infections.

Authors:  Pizzigallo Eligio; Racciatti Delia; Gorgoretti Valeria
Journal:  Mediterr J Hematol Infect Dis       Date:  2010-08-10       Impact factor: 2.576

Review 5.  BamHI-A rightward frame 1, an Epstein-Barr virus-encoded oncogene and immune modulator.

Authors:  Eveline K Hoebe; Tessa Y S Le Large; Astrid E Greijer; Jaap M Middeldorp
Journal:  Rev Med Virol       Date:  2013-08-31       Impact factor: 6.989

Review 6.  The Roles of the Virome in Cancer.

Authors:  Felix Broecker; Karin Moelling
Journal:  Microorganisms       Date:  2021-12-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.